RT Book, Section
A1 Honkonen, Marcella N.
A1 Shehab, Ziad
A1 Armstrong, Edward P.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1164046683
T1 Bone and Joint Infections
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1164046683
RD 2024/04/23
AB Content  UpdateJune  12,  2019Oral  versus  Intravenous  Antibiotics  for  Bone  and  Joint  Infection:  IV  antibiotics  have  long  been  considered  superior  to  oral  antibiotics  for  serious  infections  based  on  the  misconception  that  IV  therapy  is  “stronger”  than  oral  therapy.  A  recent  randomized  trial  (“Oral  versus  Intravenous  Antibiotics  for  Bone  and  Joint  Infection”,  or  “OVIVIA”)  found  that  oral  antibiotic  therapy  was  noninferior  to  IV  antibiotic  therapy  during  the  first  6  weeks  for  complex  bone  and  joint  infections.  The  OVIVA  trial  may  impact  standard-of-care  for  bone  and  joint  infections  and  lessen  (or  ultimately  eliminate)  the  need  for  IV  antibiotics  for  6  weeks  in  select  patients.  Using  oral  therapy  in  appropriate  patients  may  lead  to  decreased  length  of  hospital  stay,  fewer  adverse  events,  fewer  IV-related  complications,  and  overall  reduced  healthcare  costs.